Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emerge: DT120 in Major Depressive Disorder
NCT06941844Phase 3Active, not recruiting
- Sponsor
- Definium Therapeutics
- Start
- Apr 2025
- Primary completion
- May 2026
- Countries
- 1
01
Overview
A Phase 3 trial of lysergic acid diethylamide D-tartrate in major depressive disorder (MDD), sponsored by Definium Therapeutics. Started Apr 2025; status: active, not recruiting.
02
Drugs
lysergic acid diethylamide D-tartrate
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06941844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06941844.